FLGT vs. CSTL, CDNA, SERA, VRDN, GTH, BDSX, BNR, PSNL, RNLX, and VCYT
Should you be buying Fulgent Genetics stock or one of its competitors? The main competitors of Fulgent Genetics include Castle Biosciences (CSTL), CareDx (CDNA), Sera Prognostics (SERA), Viridian Therapeutics (VRDN), Genetron (GTH), Biodesix (BDSX), Burning Rock Biotech (BNR), Personalis (PSNL), Renalytix (RNLX), and Veracyte (VCYT).
Fulgent Genetics (NASDAQ:FLGT) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, analyst recommendations, media sentiment, profitability and earnings.
In the previous week, Castle Biosciences had 4 more articles in the media than Fulgent Genetics. MarketBeat recorded 5 mentions for Castle Biosciences and 1 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.76 beat Castle Biosciences' score of 0.98 indicating that Fulgent Genetics is being referred to more favorably in the media.
Fulgent Genetics presently has a consensus price target of $30.00, indicating a potential upside of 49.78%. Castle Biosciences has a consensus price target of $31.00, indicating a potential upside of 58.89%. Given Castle Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Castle Biosciences is more favorable than Fulgent Genetics.
Castle Biosciences has a net margin of -26.15% compared to Fulgent Genetics' net margin of -58.03%. Fulgent Genetics' return on equity of -3.04% beat Castle Biosciences' return on equity.
Fulgent Genetics received 164 more outperform votes than Castle Biosciences when rated by MarketBeat users. However, 62.02% of users gave Castle Biosciences an outperform vote while only 60.70% of users gave Fulgent Genetics an outperform vote.
48.1% of Fulgent Genetics shares are held by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are held by institutional investors. 31.8% of Fulgent Genetics shares are held by insiders. Comparatively, 7.7% of Castle Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Fulgent Genetics has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Comparatively, Castle Biosciences has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500.
Castle Biosciences has lower revenue, but higher earnings than Fulgent Genetics. Castle Biosciences is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.
Summary
Castle Biosciences beats Fulgent Genetics on 10 of the 18 factors compared between the two stocks.
Get Fulgent Genetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FLGT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FLGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fulgent Genetics Competitors List
Related Companies and Tools
